Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vas Narasimhan
Pharma
Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth
Novartis' CEO remains unfazed by the threat of Merck's newly approved oral PCSK9 inhibitor, Lipfendra, to his company's injectable Leqvio.
Angus Liu
Jul 21, 2026 10:36am
In Europe, Lilly exec says MFN will affect Foundayo launch
Jun 24, 2026 11:20am
Novartis CEO echoes call for EU drug pricing reform
Apr 28, 2026 4:46pm
Novartis CEO Vas Narasimhan joins Anthropic's board
Apr 15, 2026 10:36am
Novartis pledges nearly $480M to bolster China production, R&D
Mar 23, 2026 10:35am
Novartis CEO pay soars 30% to $32M in 2025
Feb 9, 2026 3:54pm
